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Introduction
Since the first description of its use by Murrell!'!, nitroglycerin has proved to be effective in the acute therapy of angina pectoris and congestive heart failure! 2 -3 ). Although the sublingual route offers quick relief of symptoms, the duration of action is limited by rapidly diminishing blood levels' 4 !. The clinical efficacy of the longer-acting oral or buccal preparations is conditioned both by the variability of the individual response, probably due to variations in absorption and rapid first-pass hepatic metabolism! 5 -6 !. Nitroglycerin ointments have proven to be of clinical benefit, but the application is inconvenient and produces variable plasma levels depending on the skin area over which a given dose is spread! 7 -8 !.
To overcome these limitations, a transdermal therapeutic system for the administration of nitroglycerin has been developed and tested in human volunteers. This application system has been shown to yield stable nitroglycerin plasma concentrations over a 24-h period! 9 " 12 !. It was the objective of our study to establish the clinical efficacy of the nitroglycerin transdermal therapeutic system (NTG-TTS):): in patients with stable angina pectoris.
Patients and methods

NTG-TTS
The NTG-TTS tested was a self-adhesive system with a contact area of 10 cm 2 , and with an internal reservoir containing 25 mg nitroglycerin, adsorbed on silicone and provided with a rate controlling membrane. Systems identical in appearance but without active drug were used as placebo.
STUDY DESIGN
The design of the study was double-blind, randomized cross-over. Patients were randomized to treatment with a TTS-system, containing 25 mgof nitroglycerin or placebo, that was applied to the lateral chest. After 12-16 h, a symptom-limited Supplied by CIBA-GEIGY BV, Arnhem, The Netherlands. No statistical significance in all data. !. All patients were familiar with the ergometer. The work load was increased every 3 min, until the appearance of anginal pain, which represented the end-point for the patient in every day life. In cases where chest pain disappeared by the application of drugs, fatigue or shortness of breath were accepted as end-points of exercise.
Initially, a standard 12-lead ECG was recorded in the supine position. During the test, ECG was continuously followed on a 3-channel oscilloscope. Recordings were made every minute of the standard limbs leads, and of leads V2, V4 and V6. Blood pressure at rest was recorded (cuff sphygmomanometer) in the supine and standing positions. During exercise, the following measurements were taken: time to onset of angina pectoris, total duration of exercise, maximal heart rate, double product (heart rate x systolic blood pressure) at symptom limited submaximal exercise. In the present study aimed at quantitating and comparing ST depression before and after drugs, the sum of ST depression in 2 leads (V4 and V6) was calculated.
PATIENTS
Ten patients (7 males and 3 females) with a mean age of 58 years (range 46-73) with stable angina pectoris were studied. All patients were in NYHA class III. Angina pectoris in all patients was documented by a positive exercise test with both typical symptoms of angina and ST depression of more than 1 mm. The history of angina pectoris ranged from 3 to 48 months (mean 14-5 months). Two patients had a myocardial infarction at least 3 months before the study. Seven patients were on beta-blocker therapy, one patient also took nifedipine. Two patients were on oral long-acting nitrates. Beta-blocker therapy was discontinued at least 48 h prior to the study period, nifedipine and long-acting oral nitrates at least 24 h. Sublingual nitroglycerin was not given at least 1 h before the exercise tests. All patients gave informed verbal consent.
STATISTICAL ANALYSIS
The Student Mest for paired data was used. A difference of P<0-05 was considered significant.
Results
The results of heart rate and blood pressure at rest in the two phases of the study are shown in Table 1 . There was no significant difference in either heart rate or blood pressure between the two phases of the study. The heart rate and the double product on symptom limited exercise is shown in Table 2 . There was no significant difference in heart rate and double product on symptom limited exercise between the two phases of the study.
The total duration of exercise and the maximal ST depression is shown in Figs 1 and 2 . respectively. The total duration of exercise was significantly longer after treatment with transdermal nitroglycerin compared with placebo (/ ) <0002). In addition, the maximal ST depression (sum of lead V4 and V6) was significantly less after treatment with transdermal nitroglycerin (P<005). In 2 patients exercise induced angina was prevented by both placebo and TTS nitroglycerin, although they had a positive exercise test in the past. In 1 patient angina developed after 3 min of exercise in the TTS nitroglycerin phase of the study, but no angina occurred on treatment with placebo, but the exercise had to be stopped after only 2 min because of exhaustion. When these 3 patients were excluded, the remaining 7 patients had anginal pain in both exercise tests. In those 7 patients angina pectoris occurred after 4-36 ±2-32 min of exercise on placebo, and after 5-64±2-72min on TTS nitroglycerin (P<0-001) (Fig. 3) . When the maximal ST segment depression was compared at the same value of heart rate (120 beats min" 1 ), no significant differences were observed between placebo-and active treatment (Fig. 4) . However, when ST segment depression was compared at a same level of exercise for both tests, treatment with nitroglycerin was shown to result in less ST segment depression 01) (Fig. 5) .
SIDE EFFECTS
On placebo, 1 patient complained about a slight local erythema after removal of the system. On TTS nitroglycerin 1 patient had moderate headache and 1 patient called for medical help because of nausea, vomiting and headache. Both patients continued with the study. Both were not used to long-acting nitrates. One patient had a nocturnal anginal attack on placebo.
Discussion
The clinical efficacy of nitroglycerin is limited by its shortness of action, mainly by first-pass metabolism in the liver, and by a variable absorption. These limitations in the use of sublingual nitroglycerin, long-acting buccal or oral nitrates and nitroglycerin ointments, have led to the development of transdermal nitroglycerin delivery systems. These systems release the drug at a constant rate by means of a reservoir, with either a rate controlling membrane, or by adsorption of the drug to a polymer gel. Human pharmacological studies by Miiller el a/.! 12 ) showed that these systems yield stable plasma levels over a 24 h period. Steady state plasma concentrations of nitroglycerin were reached within 2 h of application of the system. Removal of the system after 24 h resulted in a rapid decline in plasma levels. Additionally, a linear correlation between the transdermal dose and plasma concentrations of nitroglycerin has been reported! 12 ]. The haemodynamic effects of these transdermal nitroglycerin delivery systems have been well studied in patients with congestive heart failures. Invasive studies in these patients did show that transdermal nitroglycerin reduces pulmonary' capillary wedge pressure, and leads to an increase in stroke volume and cardiac output! ) found that patches with low doses of nitroglycerin (mean 9-5 mg) did not affect exercise tolerance in patients with angina. In contrast, patches with higher doses of nitroglycerin (mean 19mg) prolonged'exercise time 8h after application of the patch, but the beneficial effect had disappeared by 24 h.
In our study we did not observe a change in resting heart rate during treatment with TTS-NTG. In addition, in agreement with Miiller el al.\ n \ we did not find a fall in resting supine blood pressure during TTS-NTG compared with placebo. In our study, a significant improvement was seen in the total duration of exercise and the time of onset of angina pectoris 16 h after the single application of TTS nitroglycerin (25 mg per 10 cm 2 ), compared with placebo. No individual patient had better results in any of the parameters monitored on placebo than on TTS-NTG. In regard to the total duration of exercise, 8 of 10 patients improved during the TTS-NTG phase of the study. Maximal ST segment depression was also significantly lower on TTS-NTG.
It can be concluded from our study and the other studies mentioned above, that single application of transdermal nitroglycerin patches is effective prophylaxis of exercise induced angina pectoris. Whether the same holds true for the long-term treatment, remains to be established.
In a 4-week cross-over study, Georgopoulus el a/ ( 18 ) found that NTG-TTS reduced the daily frequency of anginal attacks by 67%, and the daily consumption of nitrates by 63%. However, in a recent clinical trial TTS nitroglycerin given for I week did not affect nitroglycerin consumption, exercise tolerance or episodes of ST segment depressionl 20 ). It is obvious that more long-term studies of continuous transdermal nitroglycerin in the treatment of chronic angina pectoris are needed. It is-concluded that transdermal nitroglycerin delivery syStenW'offcr a promising, convenient and well
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tolerated approach in the treatment of patients with stable angina pectoris. The clinical efficacy of nitroglycerin in combination with this convenience of use, might ensure patient compliance.
